Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

First Posted Date
2023-10-23
Last Posted Date
2024-12-03
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
20
Registration Number
NCT06094140
Locations
🇦🇺

GenesisCare North Shore, Sydney, New South Wales, Australia

🇦🇺

Wollongong Hospital, Wollongong, New South Wales, Australia

🇦🇺

Warringal Private Hospital, Melbourne, Victoria, Australia

Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-10-12
Last Posted Date
2024-10-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
99
Registration Number
NCT06078709
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

First Posted Date
2023-10-02
Last Posted Date
2023-10-06
Lead Sponsor
Presage Biosciences
Target Recruit Count
15
Registration Number
NCT06062602
Locations
🇺🇸

LSU Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Cincinnati Health, Cincinnati, Ohio, United States

and more 1 locations

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

First Posted Date
2023-09-28
Last Posted Date
2024-12-20
Lead Sponsor
Genmab
Target Recruit Count
42
Registration Number
NCT06057038
Locations
🇯🇵

National Cancer Center East, Kashiwa, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Japan

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

First Posted Date
2023-09-08
Last Posted Date
2023-09-08
Lead Sponsor
Ukrainian Society of Clinical Oncology
Target Recruit Count
758
Registration Number
NCT06028737
Locations
🇺🇦

National Cancer Institute, Kyiv, Ukraine

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

First Posted Date
2023-09-05
Last Posted Date
2024-03-15
Lead Sponsor
Shandong Boan Biotechnology Co., Ltd
Target Recruit Count
510
Registration Number
NCT06022861
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, China

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

First Posted Date
2023-08-31
Last Posted Date
2024-05-16
Lead Sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Target Recruit Count
57
Registration Number
NCT06019130
Locations
🇩🇪

Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany

🇩🇪

Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany

🇩🇪

Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany

and more 28 locations

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

First Posted Date
2023-08-25
Last Posted Date
2024-05-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
42
Registration Number
NCT06011772
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Akeso
Target Recruit Count
90
Registration Number
NCT05960955
Locations
🇨🇳

Tianjin Provincial Tumor Hospital, Tianjin, China

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

First Posted Date
2023-07-14
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
66
Registration Number
NCT05945823
Locations
🇺🇸

University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States

🇺🇸

Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 19 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy